ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
HKD 5.36
(-1.83%)
HKD 5.36
(-1.83%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -367.55 Million | -238.71 Million | -190.54 Million |
| Net Income | -379.45 Million | -402.89 Million | -732.94 Million |
| Depreciation & Amortization | 22.58 Million | 17.61 Million | 13.17 Million |
| Deferred income taxes | - | 29.4 Million | 518.32 Million |
| Stock-based compensation | 71.64 Million | 103.82 Million | 34.01 Million |
| Change in working capital | -75.31 Million | 22.05 Million | -24.07 Million |
| Other non-cash items | -5.14 Million | -8.71 Million | 965 Thousand |
| Investing Cash Flow | -294.84 Million | 49 Thousand | -108.72 Million |
| Investments in PPE | -2.69 Million | -23.22 Million | -125.25 Million |
| Acquisitions | - | - | 2.15 Million |
| Investment purchases | -525.36 Million | - | -329 Million |
| Sales/Maturities of investments | 222.39 Million | - | 352.65 Million |
| Other Investing Activities | 10.81 Million | 23.27 Million | -9.27 Million |
| Financing Cash Flow | 331.03 Million | 179.38 Million | 793.03 Million |
| Debt repayment | -59.98 Million | -6.56 Million | -10 Thousand |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | 307.79 Million | 189.57 Million | 800.97 Million |
| Other Financing Activities | -36.73 Million | -10.19 Million | -7.93 Million |
| Accounts receivables | 27 Thousand | -36.21 Thousand | 14.72 Thousand |
| Accounts payables | - | - | - |
| Inventory | - | - | - |
| Other working capital | -75.34 Million | 22.08 Million | -24.09 Million |
| Cash at beginning of period | 635.21 Million | 668.32 Million | 183.67 Million |
| Cash at end of period | 306.98 Million | 635.21 Million | 668.32 Million |
| Capital Expenditure | -2.69 Million | -23.22 Million | -125.25 Million |
| Effect of forex changes on cash | 3.13 Million | 26.16 Million | -9.11 Million |
| Net cash flow / Change in cash | -328.22 Million | -33.11 Million | 484.65 Million |
| Free Cash Flow | -370.24 Million | -261.93 Million | -315.79 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -89.05 Million | -89.82 Million | -379.45 Million | -114.76 Million | -111.88 Million | -193.2 Million |
| Depreciation & Amortization | 5.86 Million | 5.91 Million | 22.58 Million | 6.21 Million | 6.05 Million | 12.76 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 9.51 Million | 9.59 Million | 71.64 Million | 16.52 Million | 16.1 Million | 22.46 Million |
| Change in working capital | - | - | -75.31 Million | -44.14 Million | -43.04 Million | -8.48 Million |
| Other non-cash items | 7.58 Million | 7.65 Million | -5.14 Million | 6.79 Million | 6.62 Million | 76.77 Million |
| Investing Cash Flow | 21.63 Million | 21.81 Million | -294.84 Million | -141.06 Million | -137.52 Million | -50.18 Million |
| Investments in PPE | -3.33 Million | -3.36 Million | -2.69 Million | -740.39 Thousand | -721.83 Thousand | -1.52 Million |
| Acquisitions | - | - | - | -366.42 Thousand | - | 366.42 Thousand |
| Investment purchases | -33.59 Thousand | - | -525.36 Million | -391.87 Million | - | -175.69 Million |
| Sales/Maturities of investments | 46.04 Million | - | 222.39 Million | 113.59 Million | - | 126.66 Million |
| Other Investing Activities | 24.97 Million | 25.18 Million | - | -140.32 Million | -136.8 Million | -20.01 Million |
| Financing Cash Flow | 11.55 Million | 11.65 Million | 331.03 Million | 167.99 Million | 163.78 Million | 30.53 Million |
| Debt repayment | -28.18 Million | - | -59.98 Million | -30.89 Million | - | -33.9 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 307.79 Million | 301.2 Million | - | - |
| Other Financing Activities | 11.55 Million | 11.65 Million | - | 167.99 Million | 163.78 Million | 13.83 Million |
| Accounts receivables | - | - | - | -19.25 Thousand | -18.76 Thousand | 70.11 Thousand |
| Accounts payables | - | - | - | 13.74 Million | - | -6.87 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | -44.12 Million | -43.02 Million | -1.67 Million |
| Cash at beginning of period | 337.98 Million | - | 635.21 Million | 535.05 Million | - | 713.17 Million |
| Cash at end of period | 265.23 Million | -32.58 Million | 306.98 Million | 337.98 Million | -101.34 Million | 535.05 Million |
| Capital Expenditure | -3.33 Million | -3.36 Million | -2.69 Million | -740.39 Thousand | -721.83 Thousand | -1.52 Million |
| Effect of forex changes on cash | 595.28 Thousand | 600.41 Thousand | 3.13 Million | -1.51 Million | -1.47 Million | 3.17 Million |
| Net cash flow / Change in cash | -72.75 Million | -32.58 Million | -328.22 Million | -197.06 Million | -101.34 Million | -178.11 Million |
| Free Cash Flow | -69.43 Million | -70.02 Million | -370.24 Million | -130.11 Million | -126.85 Million | -145.99 Million |
3357
1907
002811
TSKB
082920
EIM